Teplizumab, the first drug that can delay the onset of type 1 diabetes, earns FDA approval after undergoing clinical trials at the Diabetes Research Institute
The Diabetes Research Institute (DRI), one of the largest and most comprehensive research centers dedicated to finding a biological cure for diabetes, is honored and excited to have been part of the recent FDA approval of the first drug, Teplizumab, which can delay onset of type 1 diabetes (T1D). As one of the clinical sites for Teplizumab, the DRI team has been instrumental in the recent milestone and extends gratitude to all volunteers, donors, and supporters for this latest achievement.
“Teplizumab is the first drug approved as a disease modifying therapy for type 1 diabetes,” said Dr. Jay S. Skyler, Deputy Director at the Diabetes Research Institute at the University of Miami Leonard M. Miller School of Medicine. “We at DRI have been working nearly 40 years on trying to develop disease modifying therapies. We participated in the studies of Teplizumab and continue to be involved in multiple studies in the space.”
For over the last 4 decades, DRI researchers have collaborated with industry and academia to prevent, and work to find a cure for T1D, which is a life-threatening autoimmune disease. Providing cutting-edge clinical research access for patients via innovative clinical trials at the DRI has been an integral part of their success and their goal to better serve the T1D community. As they celebrate the recent success of the FDA approval of Teplizumab, the DRI will continue to focus on their mission of finding a biological cure for type 1 diabetes. The DRI and the Diabetes Research Institute Foundation, the nonprofit arm of the institute charged with fundraising to support DRI efforts, were created for one reason – to cure diabetes – which is and will continue to be the singular focus until that goal is reached.
# # #
The Diabetes Research Institute (DRI) and Foundation were created for one reason – to cure diabetes – which is and will continue to be the singular focus until that goal is reached. As one of the largest and most comprehensive research centers dedicated to curing diabetes, the DRI is working to restore natural insulin production and normalize blood sugar levels without imposing other risks. Researchers have already shown that transplanted insulin-producing islet cells allow people with type 1 diabetes to live without the need for insulin injections. Some of the DRI’s islet transplant patients have been free from insulin for more than 10 years. Funding provided by the Foundation is the driving force that allows DRI scientists to pursue new and innovative ideas, and to speed these discoveries to patients. The Diabetes Research Institute Foundation is the organization of choice for those who want to Be Part of the Cure. For more information, please visit DiabetesResearch.org or call 800-321-3437.